Genflow Biosciences PLC Announces Advancements in SIRT6 Variant Patent Application
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announced significant progress in its patent application for SIRT6 variants, aimed at preventing and treating age-related diseases. The European patent application (EP 22 808 414.1), filed on May 13, 2022, has successfully cleared the Supplementary European Search Report without additional queries from the European Patent Office.
The patent application, originally filed by the University of Rochester, The Trustees of Columbia University, and the Albert Einstein College of Medicine, focuses on SIRT6 gene/protein variants, which play important roles in DNA repair, metabolism, and longevity. The application has now advanced to the national phase of the patent process, with Genflow preparing to proceed by July 7, 2025.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) ha annunciato progressi significativi nella sua domanda di brevetto per le varianti di SIRT6, mirate a prevenire e trattare le malattie legate all'età. La domanda di brevetto europea (EP 22 808 414.1), presentata il 13 maggio 2022, ha superato con successo il Rapporto di Ricerca Supplementare Europeo senza ulteriori richieste da parte dell'Ufficio Brevetti Europeo.
La domanda di brevetto, originariamente presentata dalla University of Rochester, The Trustees of Columbia University e dal Albert Einstein College of Medicine, si concentra sulle varianti del gene/proteina SIRT6, che svolgono ruoli importanti nella riparazione del DNA, nel metabolismo e nella longevità. La domanda è ora avanzata alla fase nazionale del processo di brevetto, con Genflow che si prepara a procedere entro il 7 luglio 2025.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) anunció avances significativos en su solicitud de patente para variantes de SIRT6, con el objetivo de prevenir y tratar enfermedades relacionadas con la edad. La solicitud de patente europea (EP 22 808 414.1), presentada el 13 de mayo de 2022, ha superado con éxito el Informe de Búsqueda Suplementario Europeo sin consultas adicionales por parte de la Oficina Europea de Patentes.
La solicitud de patente, presentada originalmente por la University of Rochester, The Trustees of Columbia University y el Albert Einstein College of Medicine, se centra en las variantes del gen/proteína SIRT6, que desempeñan roles importantes en la reparación del ADN, el metabolismo y la longevidad. La solicitud ha avanzado ahora a la fase nacional del proceso de patente, con Genflow preparándose para proceder antes del 7 de julio de 2025.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF)는 노화 관련 질병을 예방하고 치료하기 위한 SIRT6 변종의 특허 신청에서 중요한 진전을 발표했습니다. 2022년 5월 13일에 제출된 유럽 특허 신청(EP 22 808 414.1)은 유럽 특허청의 추가 질의 없이 보조 유럽 검색 보고서를 성공적으로 통과했습니다.
특허 신청은 University of Rochester, The Trustees of Columbia University, Albert Einstein College of Medicine이 원래 제출하였으며, DNA 복구, 대사 및 장수에 중요한 역할을 하는 SIRT6 유전자/단백질 변종에 초점을 맞추고 있습니다. 이 신청은 이제 특허 절차의 국가 단계로 진행되었으며, Genflow는 2025년 7월 7일 이전에 진행할 준비를 하고 있습니다.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) a annoncé des progrès significatifs dans sa demande de brevet pour des variantes de SIRT6, visant à prévenir et traiter les maladies liées à l'âge. La demande de brevet européen (EP 22 808 414.1), déposée le 13 mai 2022, a réussi à franchir le Rapport de Recherche Supplémentaire Européen sans demandes supplémentaires de l'Office Européen des Brevets.
La demande de brevet, initialement déposée par la University of Rochester, The Trustees of Columbia University et le Albert Einstein College of Medicine, se concentre sur les variantes du gène/protéine SIRT6, qui jouent des rôles importants dans la réparation de l'ADN, le métabolisme et la longévité. La demande a maintenant avancé à la phase nationale du processus de brevet, Genflow se préparant à procéder d'ici le 7 juillet 2025.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) hat bedeutende Fortschritte bei seiner Patentanmeldung für SIRT6-Varianten angekündigt, die darauf abzielen, altersbedingte Krankheiten zu verhindern und zu behandeln. Der europäische Patentantrag (EP 22 808 414.1), der am 13. Mai 2022 eingereicht wurde, hat den Ergänzenden Europäischen Suchbericht erfolgreich ohne zusätzliche Anfragen des Europäischen Patentamtes bestanden.
Der Patentantrag, der ursprünglich von der University of Rochester, The Trustees of Columbia University und dem Albert Einstein College of Medicine eingereicht wurde, konzentriert sich auf SIRT6-Gene/Proteinvarianten, die wichtige Rollen bei der DNA-Reparatur, dem Stoffwechsel und der Langlebigkeit spielen. Der Antrag ist nun in die nationale Phase des Patentverfahrens übergegangen, wobei Genflow sich darauf vorbereitet, bis zum 7. Juli 2025 fortzufahren.
- Patent application for SIRT6 variants progressing successfully through European Patent Office
- No additional questions raised during patent review process
- Advancement to national phase strengthens IP protection across Europe
- None.
LONDON, UK / ACCESS Newswire / February 20, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that its exclusive, out-licensed patent application for "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" has successfully progressed through the Supplementary European Search Report without further questions from the European Patent Office (EPO).
The European patent application (EP 22 808 414.1), originally filed on May 13, 2022, by the University of Rochester, The Trustees of Columbia University in the City of New York, and the Albert Einstein College of Medicine, marks a significant step in securing protection for SIRT6 variants, a promising innovation in age-related disease therapeutics. The SIRT6 gene/protein, is known for its critical role in DNA repair, metabolism, and longevity.
Following the EPO's assessment, no further questions were raised, allowing the application to progress to the national phase of the patent process, a critical stage in securing market-specific protections across Europe.
Key Details:
Application Title: Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases
Applicants: University of Rochester; The Trustees of Columbia University in the City of New York; Albert Einstein College of Medicine.
Patent Application Number: EP 22 808 414.1
Filing Date: 13 May 2022
Result: The application met all requirements of the European Patent Convention (EPC).
Next Steps: Genflow is preparing its intention to advance the application required by 7 July 2025.
Genflow remains focused on advancing its longevity-focused therapeutic pipeline and will continue to update stakeholders as the patent application progresses.
Dr. Eric Leire, CEO of Genflow commented: "This positive outcome represents a significant step forward in securing broad intellectual property protection for our innovative work on SIRT6 variants. This milestone strengthens our position in SIRT6-based therapeutics and accelerates our mission to develop effective treatments for age-related diseases."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
Joint Corporate Brokers |
|
Capital Plus Partners Ltd | |
Jon Critchley, +44 0203 821 6168 |
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the status of Genflow Biosciences' (GENFF) SIRT6 variant patent application in Europe?
When was Genflow's (GENFF) SIRT6 variant patent application originally filed?
What is the deadline for Genflow (GENFF) to advance their SIRT6 patent application?
Which institutions are the original applicants for Genflow's (GENFF) SIRT6 patent?
What is the purpose of Genflow's (GENFF) SIRT6 variant patent application?
